This product is a nationally controlled contraband or patented product, and the Lookchem platform doesn't provide relevant sales information.
125541-22-2Relevant academic research and scientific papers
1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains
Willoughby, Christopher A.,Rosauer, Keith G.,Hale, Jeffery J.,Budhu, Richard J.,Mills, Sander G.,Chapman, Kevin T.,MacCoss, Malcolm,Malkowitz, Lorraine,Springer, Martin S.,Gould, Sandra L.,DeMartino, Julie A.,Siciliano, Salvatore J.,Cascieri, Margaret A.,Carella, Anthony,Carver, Gwen,Holmes, Karen,Schleif, William A.,Danzeisen, Renee,Hazuda, Daria,Kessler, Joseph,Lineberger, Janet,Miller, Michael,Emini, Emilio A.
, p. 427 - 431 (2003)
A new class of 4-(aminoheterocycle)piperidine derived 1,3,4 trisubstituted pyrrolidine CCR5 antagonists is reported. Compound 4a is shown to have good binding affinity (1.8 nM) and antiviral activity in PBMC's (IC95=50 nM). Compound 4a also has improved PK properties relative to 1.
Enabling Reductive C-N Cross-Coupling of Nitroalkanes and Boronic Acids by Steric Design of P(III)/P(V)=O Catalysts
Hong, Seung Youn,Kanda, Yuzuru,Li, Gen,Radosevich, Alexander T.
, (2022/05/20)
An organophosphorus-catalyzed C-N bond-forming reductive coupling of nitroalkanes with arylboronic acids and esters is reported. The method shows excellent chemoselectivity for the nitro/boronic acid substrate pair, allowing the synthesis of N-(hetero)arylamines rich in functionalization. The identification of a sterically reduced phosphetane catalyst capable of productive coupling in the P(III)/P(V)=O redox manifold is the key enabling development. Combined experimental kinetics and computational mechanistic studies show that the sterically reduced catalyst affects post-rate-limiting steps to enable the C-N coupling event in preference to deleterious side-paths.
FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE
-
Paragraph 0196, (2021/07/24)
Described is the preparation of novel fentanyl haptens of Formula (1) through (6) and their use in the preparation of effective fentanyl vaccines.
AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS
-
Paragraph 0250; 0258, (2021/04/23)
Disclosed herein are methods, pharmaceutical compositions, and vaccines for modulating an immune response. Also disclosed herein are methods, pharmaceutical compositions, and vaccines for inducing an immune response.
Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer's disease
Manzoor, Shoaib,Gabr, Moustafa T.,Rasool, Bisma,Pal, Kavita,Hoda, Nasimul
, (2021/09/28)
Development of multitargeted ligands have demonstrated remarkable efficiency as potential therapeutics for Alzheimer's disease (AD). Herein, we reported a new series of deoxyvasicinone analogues as dual inhibitor of acetylcholinesterase (AChE) and tau aggregation that function as multitargeted ligands for AD. All the multitargeted ligands 11(a-j) and 15(a-g) were designed, synthesized, and validated by 1HNMR, 13CNMR and mass spectrometry. All the synthesized compounds 11(a-j) and 15(a-g) were screened for their ability to inhibit AChE, BACE1, amyloid fibrillation, α-syn aggregation, and tau aggregation. All the screened compounds possessed weak inhibition of BACE-1, Aβ42 and α-syn aggregation. However, several compounds were identified as potential hits in the AChE inhibitory screening assay and cellular tau aggregation screening. Among all compounds, 11f remarkably inhibited AChE activity and cellular tau oligomerization at single-dose screening (10 μM). Moreover, 11f displayed a half-maximal inhibitory concentration (IC50) value of 0.91 ± 0.05 μM and half-maximal effective concentration (EC50) value of 3.83 ± 0.51 μM for the inhibition of AChE and cellular tau oligomerization, respectively. In addition, the neuroprotective effect of 11f was determined in tau-expressing SH-SY5Y cells incubated with Aβ oligomers. These findings highlighted the potential of 11f to function as a multifunctional ligand for the development of promising anti-AD drugs.
Pyrimidyl piperazine urea TRPV1 antagonistic/MOR agonistic double-target compound as well as preparation method and application thereof
-
Paragraph 0060; 0063, (2021/08/28)
The invention discloses a pyrimidinyl piperazine urea TRPV1 antagonistic/MOR agonistic double-target compound or a pharmaceutically acceptable salt thereof, the compound has a structural general formula I, and a drug taking the compound as an active component not only shows obvious inhibitory activity on TRPV1, but also can show obvious agonistic activity on MOR. The invention also discloses a preparation method of the compound or the pharmaceutically acceptable salt thereof. The preparation method has the characteristic of mild reaction conditions. The invention also discloses application of the compound or the pharmaceutically acceptable salt thereof in preparation of a medicine for treating and/or preventing TRPV1 and/or MOR mediated diseases, the medicine not only can block pain transmission of peripheral and central nervous systems, but also can reduce side effects related to single targeting, such as nausea, sleepiness and respiratory depression caused by an MOR agonist and nociceptive thermal inductance weakening and obvious body temperature rise caused by a TRPV1 antagonist, and has a good application prospect.
Benzyl piperazine urea TRPV1 antagonistic and MOR agonistic double-target drug as well as preparation method and application thereof
-
Paragraph 0047-0051; 0073-0077, (2021/08/25)
The invention belongs to the technical field of pharmacy, and particularly discloses a benzyl piperazine urea TRPV1 antagonistic and MOR agonistic double-target drug and a preparation method and application thereof, and particularly relates to a compound in general formula (I) and a pharmaceutically acceptable salt thereof, which can be used for preventing and/or treating diseases related to TRPV1 and/or MOR activity. , Immune dysfunction, neurological and psychiatric disorders, respiratory diseases, urinary and reproductive disorders. The invention also relates to a preparation method of the compounds and a pharmaceutical preparation containing the compounds.
Synthesis and antimalarial activity of 1,4-disubstituted piperidine derivatives
Seck, Rokhyatou,Gassama, Abdoulaye,Cojean, Sandrine,Cavé, Christian
, (2020/01/31)
In order to prepare, at low cost, new compounds active against Plasmodium falciparum, and with a less side-effects, we have designed and synthesized a library of 1,4-disubstituted piperidine derivatives from 4-aminopiperidine derivatives 6. The resulting compound library has been evaluated against chloroquine-sensitive (3D7) and chloroquine-resistant (W2) strains of P. falciparum. The most active molecules—compounds 12d (13.64 nM (3D7)), 13b (4.19 nM (3D7) and 13.30 nM (W2)), and 12a (11.6 nM (W2))—were comparable to chloroquine (22.38 nM (3D7) and 134.12 nM (W2)).
Catalyst-Free Reductive Coupling of Aromatic and Aliphatic Nitro Compounds with Organohalides
Rauser, Marian,Eckert, Raphael,Gerbershagen, Max,Niggemann, Meike
, p. 6713 - 6717 (2019/04/14)
A rare reductive coupling of nitro compounds with organohalides has been realized. The reaction is initiated by a partial reduction of the nitro group to a nitrenoid intermediate. Therefore, not only aromatic but also aliphatic nitro compounds are efficiently transformed into monoalkylated amines, with organohalides as the alkylating agent. Given the innate reactivity of the nitrenoid, a catalyst is not required, resulting in a high tolerance for aryl halide substituents in both starting materials.
Synthetic route towards potential bivalent ligands possessing opioid and D2/D3 pharmacophores
Jevti?, Ivana I.,Penji?evi?, Jelena Z.,Ivanovi?, Milovan D.,Kosti?-Raja?i?, Sla?ana V.
, p. 639 - 647 (2019/08/30)
A scalable, cost-efficient and simple synthetic pathway towards potential bivalent opioid/dopamine receptor ligands was developed and optimized. Three novel compounds that contain both opioid and dopamine pharmacophores linked by the four methylene group chain were synthesized in 33, 35 and 39 % overall yield after a four-step synthetic route starting from three commercially available N-aryl piperazines. The anilino piperidine precursor was easily prepared in three steps, as previously published, starting from 4-piperidone. The synthesis presented in this paper could be of interest for heterocyclic and general organic chemistry. The newly designed compounds possessing two pharmacophores, opioid and D2/D3, are potentially useful pharmacological probes. Of particular interest would be the simultaneous binding to both opioid and D2/D3 receptors, and the resulting pharmacological responses may be useful for the further understanding of tolerance and dependence phenomena in opioid clinical use and/or abuse.